HHS advances peptide plan; China curbs biotech exports — SkimNews
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- HHS is proceeding with a plan to allow compounding pharmacies to produce certain peptides, a class of largely unregulated injections popular with Secretary Robert F. Kennedy Jr. and wellness influencers, per the Associated Press.
- The peptides under HHS consideration have not been FDA-approved as safe or effective, and most of the available supporting data come from animal studies.
- China's Ministry of Commerce is proposing to add five biomedical technologies to its export-control list, per Bloomberg Law, including two types of medical technology platforms designed to treat diseases at the genetic level.
- Beijing's draft proposal exempts licensing deals, partnerships, and contract research services with foreign drugmakers — the channels that have underpinned China's position as a growing pharmaceutical powerhouse.
Why it matters: HHS is proceeding on a peptide compounding plan for compounds the FDA has not approved as safe or effective. China's proposed biotech export curbs still exempt licensing deals and partnerships with foreign drugmakers — the channels that have underpinned its pharmaceutical growth — so foreign drugmakers retain access even as manufacturing tightens.
Ask SkimNews
